These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 29382703)

  • 41. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
    Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S
    Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
    Milne RL; Antoniou AC
    Ann Oncol; 2011 Jan; 22 Suppl 1():i11-7. PubMed ID: 21285145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
    Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk.
    Lianos GD; Zoras O; Roukos DH
    Biomark Med; 2013 Oct; 7(5):675-8. PubMed ID: 24044557
    [No Abstract]   [Full Text] [Related]  

  • 47. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.
    Antoniou AC; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; McGuffog L; Lee A; Barrowdale D; Healey S; Sinilnikova OM; Caligo MA; Loman N; Harbst K; Lindblom A; Arver B; Rosenquist R; Karlsson P; Nathanson K; Domchek S; Rebbeck T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Złowowcka-Perłowska E; Osorio A; Durán M; Andrés R; Benítez J; Hamann U; Hogervorst FB; van Os TA; Verhoef S; Meijers-Heijboer HE; Wijnen J; Gómez Garcia EB; Ligtenberg MJ; Kriege M; Collée JM; Ausems MG; Oosterwijk JC; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Jacobs C; Eeles R; Adlard J; Davidson R; Cole T; Cook J; Paterson J; Douglas F; Brewer C; Hodgson S; Morrison PJ; Walker L; Rogers MT; Donaldson A; Dorkins H; Godwin AK; Bove B; Stoppa-Lyonnet D; Houdayer C; Buecher B; de Pauw A; Mazoyer S; Calender A; Léoné M; Bressac-de Paillerets B; Caron O; Sobol H; Frenay M; Prieur F; Ferrer SU; Mortemousque I; Buys S; Daly M; Miron A; Terry MU; Hopper JL; John EM; Southey M; Goldgar D; Singer CF; Fink-Retter A; Tea MK; Kaulich DU; Hansen TV; Nielsen FC; Barkardottir RB; Gaudet M; Kirchhoff T; Joseph V; Dutra-Clarke A; Offit K; Piedmonte M; Kirk J; Cohn D; Hurteau J; Byron J; Fiorica J; Toland AE; Montagna M; Oliani C; Imyanitov E; Isaacs C; Tihomirova L; Blanco I; Lazaro C; Teulé A; Valle JD; Gayther SA; Odunsi K; Gross J; Karlan BY; Olah E; Teo SH; Ganz PA; Beattie MS; Dorfling CM; van Rensburg EU; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Schäfer D; Caldes T; de la Hoya M; Nevanlinna H; Muranen TA; Lespérance B; Spurdle AB; Neuhausen SL; Ding YC; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Bonanni B; Bernard L; Dolcetti R; Papi L; Ottini L; Radice P; Greene MH; Loud JT; Andrulis IL; Ozcelik H; Mulligan AU; Glendon G; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Chenevix-Trench G; Couch FJ; Simard J; Easton DF; ; ; ; ;
    Breast Cancer Res; 2012 Feb; 14(1):R33. PubMed ID: 22348646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer.
    Gaudet MM; Kirchhoff T; Green T; Vijai J; Korn JM; Guiducci C; Segrè AV; McGee K; McGuffog L; Kartsonaki C; Morrison J; Healey S; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Gauthier-Villars M; Sobol H; Longy M; Frenay M; GEMO Study Collaborators ; Hogervorst FB; Rookus MA; Collée JM; Hoogerbrugge N; van Roozendaal KE; ; Piedmonte M; Rubinstein W; Nerenstone S; Van Le L; Blank SV; Caldés T; de la Hoya M; Nevanlinna H; Aittomäki K; Lazaro C; Blanco I; Arason A; Johannsson OT; Barkardottir RB; Devilee P; Olopade OI; Neuhausen SL; Wang X; Fredericksen ZS; Peterlongo P; Manoukian S; Barile M; Viel A; Radice P; Phelan CM; Narod S; Rennert G; Lejbkowicz F; Flugelman A; Andrulis IL; Glendon G; Ozcelik H; ; Toland AE; Montagna M; D'Andrea E; Friedman E; Laitman Y; Borg A; Beattie M; Ramus SJ; Domchek SM; Nathanson KL; Rebbeck T; Spurdle AB; Chen X; Holland H; ; John EM; Hopper JL; Buys SS; Daly MB; Southey MC; Terry MB; Tung N; Overeem Hansen TV; Nielsen FC; Greene MH; Mai PL; Osorio A; Durán M; Andres R; Benítez J; Weitzel JN; Garber J; Hamann U; ; Peock S; Cook M; Oliver C; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Walker L; Eason J; Barwell J; Godwin AK; Schmutzler RK; Wappenschmidt B; Engert S; Arnold N; Gadzicki D; Dean M; Gold B; Klein RJ; Couch FJ; Chenevix-Trench G; Easton DF; Daly MJ; Antoniou AC; Altshuler DM; Offit K
    PLoS Genet; 2010 Oct; 6(10):e1001183. PubMed ID: 21060860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers.
    Borde J; Ernst C; Wappenschmidt B; Niederacher D; Weber-Lassalle K; Schmidt G; Hauke J; Quante AS; Weber-Lassalle N; Horváth J; Pohl-Rescigno E; Arnold N; Rump A; Gehrig A; Hentschel J; Faust U; Dutrannoy V; Meindl A; Kuzyakova M; Wang-Gohrke S; Weber BHF; Sutter C; Volk AE; Giannakopoulou O; Lee A; Engel C; Schmidt MK; Antoniou AC; Schmutzler RK; Kuchenbaecker K; Hahnen E
    J Natl Cancer Inst; 2021 Jul; 113(7):893-899. PubMed ID: 33372680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
    Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
    BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer.
    Haytural H; Yalcinkaya N; Akan G; Arikan S; Ozkok E; Cakmakoglu B; Yaylim I; Aydin M; Atalar F
    Asian Pac J Cancer Prev; 2013; 14(5):3229-35. PubMed ID: 23803109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
    Milne RL; Antoniou AC
    Endocr Relat Cancer; 2016 Oct; 23(10):T69-84. PubMed ID: 27528622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.
    Malone KE; Begg CB; Haile RW; Borg A; Concannon P; Tellhed L; Xue S; Teraoka S; Bernstein L; Capanu M; Reiner AS; Riedel ER; Thomas DC; Mellemkjaer L; Lynch CF; Boice JD; Anton-Culver H; Bernstein JL
    J Clin Oncol; 2010 May; 28(14):2404-10. PubMed ID: 20368571
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Next-Generation Sequencing Identifies
    Peker Eyüboğlu İ; Yenmiş G; Bingöl EN; Yüksel Ş; Tokat F; Özbek P; Güllü Amuran G; Yakıcıer C; Akkiprik M
    OMICS; 2020 Jan; 24(1):5-15. PubMed ID: 31851867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
    Desjardins S; Belleau P; Labrie Y; Ouellette G; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; ; Durocher F
    Int J Cancer; 2008 Jan; 122(1):108-16. PubMed ID: 17764113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
    Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
    Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Garcia AI; Cox DG; Barjhoux L; Verny-Pierre C; Barnes D; ; Antoniou AC; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S
    Hum Mutat; 2011 Sep; 32(9):1004-7. PubMed ID: 21591024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.